Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

NCT00549601 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
DRUG: Rivastigmine patch (9.5 mg/day)
DRUG: Rivastigmine capsules (6 mg to 12 mg/day)

Sponsor

Novartis